We retain our positive view on Genovis and are reviewing our forecasts with an upward bias following company visits and a review of the case. While continued gradual recovery in all key markets bodes well in the longer term, Genovis’ resilience in these challenging times (winning new customers is currently very difficult) is a real quality stamp. The shares remain on Redeye’s Conviction Buy List.